CA3128327A1 - A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl - Google Patents
A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl Download PDFInfo
- Publication number
- CA3128327A1 CA3128327A1 CA3128327A CA3128327A CA3128327A1 CA 3128327 A1 CA3128327 A1 CA 3128327A1 CA 3128327 A CA3128327 A CA 3128327A CA 3128327 A CA3128327 A CA 3128327A CA 3128327 A1 CA3128327 A1 CA 3128327A1
- Authority
- CA
- Canada
- Prior art keywords
- kar5585
- mean
- dose
- day
- kar5417
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical group CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 title claims abstract description 396
- 238000000034 method Methods 0.000 title claims abstract description 57
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title claims abstract description 41
- ZNSPHKJFQDEABI-NZQKXSOJSA-N Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 Chemical compound Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 ZNSPHKJFQDEABI-NZQKXSOJSA-N 0.000 claims abstract description 220
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 claims abstract description 194
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 178
- 229940076279 serotonin Drugs 0.000 claims abstract description 48
- 230000009467 reduction Effects 0.000 claims abstract description 21
- 239000002552 dosage form Substances 0.000 claims abstract description 18
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 14
- 230000002485 urinary effect Effects 0.000 claims abstract description 9
- 241000282414 Homo sapiens Species 0.000 claims description 34
- 239000006186 oral dosage form Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 description 91
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 91
- 210000002700 urine Anatomy 0.000 description 72
- 239000000090 biomarker Substances 0.000 description 54
- 239000000902 placebo Substances 0.000 description 53
- 229940068196 placebo Drugs 0.000 description 53
- 230000008859 change Effects 0.000 description 48
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 38
- 235000020937 fasting conditions Nutrition 0.000 description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 28
- 230000009246 food effect Effects 0.000 description 27
- 230000036470 plasma concentration Effects 0.000 description 27
- 235000021471 food effect Nutrition 0.000 description 26
- 201000010099 disease Diseases 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 239000003112 inhibitor Substances 0.000 description 21
- 229940109239 creatinine Drugs 0.000 description 19
- 238000009825 accumulation Methods 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 230000008030 elimination Effects 0.000 description 17
- 238000003379 elimination reaction Methods 0.000 description 17
- 230000009885 systemic effect Effects 0.000 description 17
- 238000010521 absorption reaction Methods 0.000 description 16
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- 238000000634 powder X-ray diffraction Methods 0.000 description 13
- 239000000651 prodrug Substances 0.000 description 13
- 229940002612 prodrug Drugs 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 101000830742 Homo sapiens Tryptophan 5-hydroxylase 1 Proteins 0.000 description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 description 12
- 230000002093 peripheral effect Effects 0.000 description 12
- 102100024971 Tryptophan 5-hydroxylase 1 Human genes 0.000 description 11
- 239000002775 capsule Substances 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 10
- 238000001647 drug administration Methods 0.000 description 10
- 230000029142 excretion Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000001174 ascending effect Effects 0.000 description 8
- 235000010290 biphenyl Nutrition 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 208000002815 pulmonary hypertension Diseases 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 206010007270 Carcinoid syndrome Diseases 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 101000892398 Homo sapiens Tryptophan 2,3-dioxygenase Proteins 0.000 description 4
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 4
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 4
- 229940127410 Tryptophan Hydroxylase Inhibitors Drugs 0.000 description 4
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 4
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 4
- 238000013103 analytical ultracentrifugation Methods 0.000 description 4
- 208000002458 carcinoid tumor Diseases 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000005176 gastrointestinal motility Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000851865 Homo sapiens Tryptophan 5-hydroxylase 2 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 description 3
- 102100036474 Tryptophan 5-hydroxylase 2 Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- PPDNGMUGVMESGE-JTQLQIEISA-N (2s)-2-amino-3-(4-ethynylphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(C#C)C=C1 PPDNGMUGVMESGE-JTQLQIEISA-N 0.000 description 2
- HNXQXTQTPAJEJL-UHFFFAOYSA-N 2-aminopteridin-4-ol Chemical compound C1=CN=C2NC(N)=NC(=O)C2=N1 HNXQXTQTPAJEJL-UHFFFAOYSA-N 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 2
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 206010007275 Carcinoid tumour Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- -1 Phenylalanine Series Compounds Chemical class 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 description 2
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000011128 cardiac conduction Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 201000001937 osteoporosis-pseudoglioma syndrome Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000036325 urinary excretion Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 102000006969 5-HT2B Serotonin Receptor Human genes 0.000 description 1
- 108010072584 5-HT2B Serotonin Receptor Proteins 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000008884 Aneurysmal Bone Cysts Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 102000000632 Aromatic amino acid hydroxylases Human genes 0.000 description 1
- 108050008079 Aromatic amino acid hydroxylases Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010005969 Bone giant cell tumour Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 208000010126 Chondromatosis Diseases 0.000 description 1
- 208000019591 Chondromyxoid fibroma Diseases 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000029147 Collagen-vascular disease Diseases 0.000 description 1
- 201000005078 Colonic Pseudo-Obstruction Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000034715 Enchondroma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 241001069765 Fridericia <angiosperm> Species 0.000 description 1
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
- 206010017969 Gastrointestinal inflammatory conditions Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 1
- 208000021124 Heritable pulmonary arterial hypertension Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000631929 Homo sapiens Sodium-dependent serotonin transporter Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100370134 Mus musculus Tph1 gene Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001715 Osteoblastoma Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000035467 Pancreatic insufficiency Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 description 1
- 101100537702 Rattus norvegicus Tph1 gene Proteins 0.000 description 1
- 244000292604 Salvia columbariae Species 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 206010040108 Serotonin syndrome Diseases 0.000 description 1
- 102100028874 Sodium-dependent serotonin transporter Human genes 0.000 description 1
- 208000033039 Somatisation disease Diseases 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229940116984 Tryptophan 5 hydroxylase inhibitor Drugs 0.000 description 1
- 102000004271 Tryptophan 5-monooxygenases Human genes 0.000 description 1
- 108090000885 Tryptophan 5-monooxygenases Proteins 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000037884 allergic airway inflammation Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- 208000005761 carcinoid heart disease Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000037876 carotid Atherosclerosis Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 201000003617 glucocorticoid-induced osteoporosis Diseases 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000056704 human TPH2 Human genes 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002071 myeloproliferative effect Effects 0.000 description 1
- 210000003249 myenteric plexus Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 208000003388 osteoid osteoma Diseases 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000011116 pancreatic cholera Diseases 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 208000004594 persistent fetal circulation syndrome Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000006409 renal osteodystrophy Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000028528 solitary bone cyst Diseases 0.000 description 1
- 208000016994 somatization disease Diseases 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962798827P | 2019-01-30 | 2019-01-30 | |
| US62/798,827 | 2019-01-30 | ||
| PCT/IB2020/000074 WO2020157577A1 (en) | 2019-01-30 | 2020-01-30 | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3128327A1 true CA3128327A1 (en) | 2020-08-06 |
Family
ID=70285725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3128327A Pending CA3128327A1 (en) | 2019-01-30 | 2020-01-30 | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11607413B2 (https=) |
| EP (1) | EP3917531A1 (https=) |
| JP (1) | JP2022518944A (https=) |
| KR (1) | KR20210133953A (https=) |
| CN (1) | CN113557022A (https=) |
| AU (1) | AU2020213746A1 (https=) |
| CA (1) | CA3128327A1 (https=) |
| MX (1) | MX2021009055A (https=) |
| WO (1) | WO2020157577A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210102887A (ko) * | 2018-11-14 | 2021-08-20 | 알타반트 사이언시스 게엠베하 | 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제 |
| JP2022507533A (ja) * | 2018-11-16 | 2022-01-18 | アルタバント・サイエンシズ・ゲーエムベーハー | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 |
| US20200188399A1 (en) * | 2018-12-17 | 2020-06-18 | Altavant Sciences Gmbh | Method for treating interstitial lung disease |
| US11607413B2 (en) | 2019-01-30 | 2023-03-21 | Altavant Sciences Gmbh | Dosage regime and method for treating pulmonary arterial hypertension |
| US11576915B2 (en) | 2019-03-15 | 2023-02-14 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
| WO2023062595A1 (en) | 2021-10-14 | 2023-04-20 | Altavant Sciences Gmbh | Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101815534A (zh) | 2007-07-11 | 2010-08-25 | 莱西肯医药有限公司 | 用于治疗肺动脉高压以及相关疾病和病症的方法和组合物 |
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| KR20210102887A (ko) | 2018-11-14 | 2021-08-20 | 알타반트 사이언시스 게엠베하 | 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제 |
| JP2022507533A (ja) | 2018-11-16 | 2022-01-18 | アルタバント・サイエンシズ・ゲーエムベーハー | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 |
| US20200188399A1 (en) | 2018-12-17 | 2020-06-18 | Altavant Sciences Gmbh | Method for treating interstitial lung disease |
| WO2020128608A1 (en) | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension |
| US11607413B2 (en) | 2019-01-30 | 2023-03-21 | Altavant Sciences Gmbh | Dosage regime and method for treating pulmonary arterial hypertension |
| US11576915B2 (en) * | 2019-03-15 | 2023-02-14 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
-
2020
- 2020-01-30 US US16/777,458 patent/US11607413B2/en active Active
- 2020-01-30 JP JP2021544351A patent/JP2022518944A/ja active Pending
- 2020-01-30 AU AU2020213746A patent/AU2020213746A1/en not_active Abandoned
- 2020-01-30 CN CN202080016400.5A patent/CN113557022A/zh active Pending
- 2020-01-30 CA CA3128327A patent/CA3128327A1/en active Pending
- 2020-01-30 EP EP20718760.0A patent/EP3917531A1/en not_active Withdrawn
- 2020-01-30 MX MX2021009055A patent/MX2021009055A/es unknown
- 2020-01-30 KR KR1020217024232A patent/KR20210133953A/ko not_active Abandoned
- 2020-01-30 WO PCT/IB2020/000074 patent/WO2020157577A1/en not_active Ceased
-
2023
- 2023-01-25 US US18/159,494 patent/US20240041877A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US11607413B2 (en) | 2023-03-21 |
| JP2022518944A (ja) | 2022-03-17 |
| CN113557022A (zh) | 2021-10-26 |
| US20200237759A1 (en) | 2020-07-30 |
| AU2020213746A1 (en) | 2021-08-19 |
| WO2020157577A8 (en) | 2020-10-15 |
| MX2021009055A (es) | 2021-10-22 |
| WO2020157577A1 (en) | 2020-08-06 |
| EP3917531A1 (en) | 2021-12-08 |
| US20240041877A1 (en) | 2024-02-08 |
| KR20210133953A (ko) | 2021-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3128327A1 (en) | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl | |
| US20260091037A1 (en) | Methods for increasing sepiapterin plasma exposure | |
| Giorgi et al. | Pharmacokinetics of tramadol and its metabolites M1, M2 and M5 in horses following intravenous, immediate release (fasted/fed) and sustained release single dose administration | |
| CA2769531C (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| WO2012054813A1 (en) | Novel methods for treating breathing disorders or diseases | |
| KR101996245B1 (ko) | 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물 | |
| US12257252B2 (en) | Compositions and methods for increasing tetrahydrobiopterin plasma exposure | |
| Lynch III et al. | ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model | |
| US20240197756A1 (en) | Methods of treatment with neuroactive steroids | |
| US10172854B2 (en) | Compositions and methods for treating mitochondrial diseases | |
| HK40062167A (en) | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl | |
| TW201934123A (zh) | 預防或治療癌症之包含pi3激酶抑制劑與細胞毒性抗癌物的醫藥組成物 | |
| HK40119071A (en) | Methods for increasing sepiapterin plasma exposure | |
| KR100701409B1 (ko) | 호박산 수마트립탄을 함유하는 약제학적 조성물 | |
| HK40051961A (en) | Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure | |
| HK40051961B (en) | Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure | |
| KR20070091911A (ko) | 약물의존중독을 예방 및 치료하기 위한 바닐로이드 수용체길항제 | |
| HK1172242B (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| HK1172242A (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| JP2010222347A (ja) | Ｐｄｅ５阻害剤及びカルニチンを含有する医薬組成物 |